Skip to main content
x

Recent articles

FDA red and green lights: April 2025

April saw a checkpoint inhibitor bonanza for Bristol and Akeso.

AACR 2025 – BioNTech sees its first combo glimmers

A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.

AACR 2025 – an academic reminder about Jemperli

An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.

AACR 2025 – a requiem for Roche's TIGIT

Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.

Astra stumbles again with Truqap

The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.

AACR 2025 – Boehringer still has broad zongertinib hopes

Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.